Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - ImmunoCellular Therapeutics, Ltd. | imuc-93016xexhibit322.htm |
| EX-31.2 - EXHIBIT 31.2 - ImmunoCellular Therapeutics, Ltd. | imuc-93016xexhibit312.htm |
| EX-31.1 - EXHIBIT 31.1 - ImmunoCellular Therapeutics, Ltd. | imuc-93016xexhibit311.htm |
| EX-10.1 - EXHIBIT 10.1 - ImmunoCellular Therapeutics, Ltd. | imuc-93016xexhibit1011.htm |
| EX-4.1 - EXHIBIT 4.1 - ImmunoCellular Therapeutics, Ltd. | imuc-93016xexhibit412.htm |
| 10-Q - 10-Q - ImmunoCellular Therapeutics, Ltd. | imuc-93016x10q.htm |
Exhibit 32.1
CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
Pursuant to the requirement set forth in Rule 13a -14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), the undersigned officer of ImmunoCellular Therapeutics, Ltd. (the “Company”) hereby certifies that, to the best of his knowledge:
1. | The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2016 (“Periodic Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and |
2. | The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: November 10, 2016 | By: | /s/ Andrew Gengos | |
Name: | Andrew Gengos | ||
Title: | President and Chief Executive Officer | ||